Molecular Testing in Endometrial Cancer: An introduction from basic to practical point
Article Sidebar
Main Article Content
Abstract
Endometrial cancer exhibits significant molecular heterogeneity, requiring precise classification for optimal management. The current landscape of molecular testing is examined, focusing on the comprehensive The Cancer Genome Atlas (TCGA) classification. This system stratifies endometrial cancers into four subtypes: POLE DNA polymerase epsilon (POLE) ultra-mutated, mismatch repair deficient (dMMR), p53-abnormal, and no specific molecular profile (NSMP). Each subtype’s molecular characteristics, clinical features, and prognostic implications are detailed, including the roles of tumor mutational burden, copy number variation, and key genes such as tumor protein p53 (TP53). Molecular testing algorithms were explored. The clinical implications of each molecular subtype are discussed and emphasized their influence on prognosis and treatment. Simplified, some practical points were linked. Integrating molecular findings with clinicopathological data is highlighted as crucial for personalized patient management.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022;72:7-33.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-49.
Rojanamatin J, Ukranun W, Supaattagorn P, Chiawiriyabunya I, Wongsena M, Chaiwerawattana A, et al. Cancer in Thailand Vol X, 2016-2018, Bangkok 2021.
Imsamran W, Pattatang A, Supaattagorn P, Chiawiriyabunya I, Namthisong K, Wongsena M, et al. Cancer in Thailand Vol IX, 2013-2015. Thailand: New Thammada Press (Thailand) Co., Ltd.; 2018.
Imsamran W, Chaiwerawattana A, Wiangnon S, Pongnikorn D, Suwanrungruang K, Sangrajrang S, et al. Cancer in Thailand Vol. VIII, 2010-2012. Thailand: New Thammada Press (Thailand) Co., Ltd.; 2015.
Khuhaprema T, Attasara P, Sriplung H, Wiangnon S, Sangrajrang S. Cancer in Thailand Vol. VII, 2007-2009. Thailand: New Thammada Press (Thailand) Co., Ltd.; 2013.
Sakboonyarat B, Pornpongsawad C, Sangkool T, Phanmanas C, Kesonphaet N, Tangthongtawi N, et al. Trends, prevalence and associated factors of obesity among adults in a rural community in Thailand: serial cross-sectional surveys, 2012 and 2018. BMC Public Health 2020;20:850.
Constantine GD, Kessler G, Graham S, Goldstein SR. Increased incidence of endometrial cancer following the women’s health initiative: An assessment of risk factors. J Womens Health (Larchmt) 2019;28:237-43.
Hanprasertpong T, Hanprasertpong J. Lifestyle factors and the risk of endometrial cancer: A review. Thai J Obstet Gynaecol 2024;32:92-8.
Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-7.
Johnson JE, Daley D, Tarta C, Stanciu PI. Risk of endometrial cancer in patients with polycystic ovarian syndrome: A meta‑analysis. Oncol Lett 2023;25:168.
Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet Oncol 2014;15:e268-78.
Ribeiro-Santos P, Martins Vieira C, Viana Veloso GG, Vieira Giannecchini G, Parenza Arenhardt M, Müller Gomes L, et al. Tailoring endometrial cancer treatment based on molecular pathology: Current status and possible impacts on systemic and local treatment. Int J Mol Sci 2024;25:7742.
Hashmi AA, Iftikhar SN, Ali J, Shaheen F, Afroze F, Imran A. Morphological spectrum and pathological parameters of type 2 endometrial carcinoma: A comparison with type 1 endometrial cancers. Cureus 2020;12:e11025.
Malik TY, Chishti U, Aziz AB, Sheikh I. Comparison of risk factors and survival of type 1 and type II endometrial cancers. Pak J Med Sci. 2016;32:886-90.
Bell DW, Ellenson LH. Molecular genetics of endometrial carcinoma. Annu Rev Pathol 2019;14:339-67.
Arciuolo D, Travaglino A, Raffone A, Raimondo D, Santoro A, Russo D, et al. TCGA molecular prognostic groups of endometrial carcinoma: Current knowledge and future perspectives. Int J Mol Sci 2022;23.
Mariani A, Webb MJ, Keeney GL, Haddock MG, Calori G, Podratz KC. Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol 2000;182:1506-19.
Cusimano MC, Vicus D, Pulman K, Maganti M, Bernardini MQ, Bouchard-Fortier G, et al. Assessment of sentinel lymph node biopsy vs lymphadenectomy for intermediate- and high-grade endometrial cancer Staging. JAMA Surgery 2021;156:157-64.
Salman L, Cusimano MC, Marchocki Z, Ferguson SE. Sentinel lymph node mapping in high-grade endometrial cancer. Curr Oncol 2022;29:1123-35.
Sarah L, Olivia L, Hannah K, Bhavana P. The association of tumor mutational burden, microsatellite stability, and mismatch repair deficiency in an endometrial cancer patient cohort (194). Gynecologic Oncology 2022; 166:S111.
Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015;348:69-74.
Klempner SJ, Fabrizio D, Bane S, Reinhart M, Peoples T, Ali SM, et al. Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: A review of current evidence. Oncologist 2020;25:e147-e59.
Alexa M, Hasenburg A, Battista MJ. The TCGA molecular classification of endometrial cancer and its possible impact on adjuvant treatment decisions. cancers (basel) 2021;13.
Pös O, Radvanszky J, Buglyó G, Pös Z, Rusnakova D, Nagy B, et al. DNA copy number variation: Main characteristics, evolutionary significance, and pathological aspects. Biomed J 2021;44:548-59.
Bateman AC. DNA mismatch repair proteins: scientific update and practical guide. J Clin Pathol 2021;74:264-8.
Li GM. Mechanisms and functions of DNA mismatch repair. Cell Res 2008;18:85-98.
Martín-López JV, Fishel R. The mechanism of mismatch repair and the functional analysis of mismatch repair defects in Lynch syndrome. Fam Cancer 2013;12:159-68.
Li GM. The role of mismatch repair in DNA damage-induced apoptosis. Oncol Res 1999;11:393-400.
Karley W, Mairead D, Kyle CS, Bhavana P, Victoria B-J, Lindsay EB, et al. TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes. Gynecologic Oncology 2023;178: 44-53.
Zhao D, Tahaney WM, Mazumdar A, Savage MI, Brown PH. Molecularly targeted therapies for p53-mutant cancers. Cell Mol Life Sci 2017;74:4171-87.
Malkin D, Li FP, Strong LC, Fraumeni JF, Jr., Nelson CE, Kim DH, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-8.
Frebourg T, Kassel J, Lam KT, Gryka MA, Barbier N, Andersen TI, et al. Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein. Proc Natl Acad Sci U S A 1992;89:6413-7.
Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene: Important milestones at the various steps of tumorigenesis. Genes Cancer 2011;2:466-74.
Albertson TM, Ogawa M, Bugni JM, Hays LE, Chen Y, Wang Y, et al. DNA polymerase epsilon and delta proofreading suppress discrete mutator and cancer phenotypes in mice. Proc Natl Acad Sci U S A 2009;106:17101-4.
Morrison A, Bell JB, Kunkel TA, Sugino A. Eukaryotic DNA polymerase amino acid sequence required for 3’----5’ exonuclease activity. Proc Natl Acad Sci U S A 1991;88:9473-7.
Church DN, Briggs SE, Palles C, Domingo E, Kearsey SJ, Grimes JM, et al. DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer. Hum Mol Genet 2013;22:2820-8.
Simon M, Giot L, Faye G. The 3’ to 5’ exonuclease activity located in the DNA polymerase delta subunit of Saccharomyces cerevisiae is required for accurate replication. Embo J 1991;10:2165-70.
Pursell ZF, Isoz I, Lundström EB, Johansson E, Kunkel TA. Yeast DNA polymerase epsilon participates in leading-strand DNA replication. Science 2007;317: 127-30.
Billingsley CC, Cohn DE, Mutch DG, Stephens JA, Suarez AA, Goodfellow PJ. Polymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing. Cancer 2015;121:386-94.
Casanova J, Duarte GS, da Costa AG, Catarino A, Nave M, Antunes T, et al. Prognosis of polymerase epsilon (POLE) mutation in high-grade endometrioid endometrial cancer: Systematic review and meta-analysis. Gynecol Oncol 2024;182:99-107.
León-Castillo A, Britton H, McConechy MK, McAlpine JN, Nout R, Kommoss S, et al. Interpretation of somatic POLE mutations in endometrial carcinoma. J Pathol 2020;250:323-35.
Yao X, Feng M, Wang W. The clinical and pathological characteristics of POLE-mutated endometrial cancer: A comprehensive review. Cancer Manag Res 2024;16: 117-25.
Santoro A, Angelico G, Travaglino A, Raffone A, Arciuolo D, D’Alessandris N, et al. Clinico-pathological significance of TCGA classification and SWI/SNF proteins expression in undifferentiated/dedifferentiated endometrial carcinoma: A possible prognostic risk stratification. Gynecol Oncol 2021;161:629-35.
van Gool IC, Eggink FA, Freeman-Mills L, Stelloo E, Marchi E, de Bruyn M, et al. POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. Clin Cancer Res 2015;21:3347-55.
Stasenko M, Tunnage I, Ashley CW, Rubinstein MM, Latham AJ, Da Cruz Paula A, et al. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer. Gynecol Oncol 2020;156:194-202.
McConechy MK, Talhouk A, Leung S, Chiu D, Yang W, Senz J, et al. Endometrial carcinomas with POLE exonuclease domain mutations have a favorable prognosis. Clin Cancer Res 2016;22:2865-73.
Conlon N, Da Cruz Paula A, Ashley CW, Segura S, De Brot L, da Silva EM, et al. Endometrial carcinomas with a “Serous” component in young women are enriched for DNA mismatch repair deficiency, lynch syndrome, and POLE exonuclease domain mutations. Am J Surg Pathol 2020;44:641-8.
Murali R, Davidson B, Fadare O, Carlson JA, Crum CP, Gilks CB, et al. High-grade endometrial carcinomas: Morphologic and immunohistochemical features, diagnostic challenges and recommendations. Int J Gynecol Pathol 2019;38 Suppl 1:s40-s63.
Akdemir KC, Le VT, Kim JM, Killcoyne S, King DA, Lin YP, et al. Somatic mutation distributions in cancer genomes vary with three-dimensional chromatin structure. Nat Genet 2020;52:1178-88.
De Vitis LA, Schivardi G, Caruso G, Fumagalli C, Vacirca D, Achilarre MT, et al. Clinicopathological characteristics of multiple-classifier endometrial cancers: a cohort study and systematic review. Int J Gynecol Cancer 2024;34:229-38.
León-Castillo A, Gilvazquez E, Nout R, Smit VT, McAlpine JN, McConechy M, et al. Clinicopathological and molecular characterisation of ‘multiple-classifier’ endometrial carcinomas. J Pathol 2020;250:312-22.
Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J, et al. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer 2017;123:802-13.
McAlpine JN, Chiu DS, Nout RA, Church DN, Schmidt P, Lam S, et al. Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis. Cancer 2021;127:2409-22.
Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 2021;31:12-39.
Oaknin A, Bosse TJ, Creutzberg CL, Giornelli G, Harter P, Joly F, et al. Endometrial cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 2022;33:860-77.
Ryan NAJ, Glaire MA, Blake D, Cabrera-Dandy M, Evans DG, Crosbie EJ. The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis. Genet Med 2019;21:2167-80.
Ye M, Ru G, Yuan H, Qian L, He X, Li S. Concordance between microsatellite instability and mismatch repair protein expression in colorectal cancer and their clinicopathological characteristics: a retrospective analysis of 502 cases. Front Oncol 2023;13:1178772.
Loughrey MB, McGrath J, Coleman HG, Bankhead P, Maxwell P, McGready C, et al. Identifying mismatch repair-deficient colon cancer: near-perfect concordance between immunohistochemistry and microsatellite instability testing in a large, population-based series. Histopathology 2021;78:401-13.
Kim MK, So KA, Chun YK, Kim YH, Lim KT, Lee KH, et al. Clinicopathologic significance of mismatch repair protein expression in endometrioid endometrial cancer. Taiwan J Obstet Gynecol 2023;62:724-8.
Nagle CM, O’Mara TA, Tan Y, Buchanan DD, Obermair A, Blomfield P, et al. Endometrial cancer risk and survival by tumor MMR status. J Gynecol Oncol 2018;29:e39.
Loukovaara M, Pasanen A, Bützow R. Mismatch repair deficiency as a predictive and prognostic biomarker in molecularly classified endometrial carcinoma. Cancers (Basel) 2021;13.
Jumaah AS, Al-Haddad HS, Salem MM, McAllister KA, Yasseen AA. Mismatch repair deficiency and clinicopathological characteristics in endometrial carcinoma: a systematic review and meta-analysis. J Pathol Transl Med 2021;55:202-11.
Tresa A, Sambasivan S, Rema P, Dinesh D, Sivaranjith J, Nair SP, et al. Clinical profile and survival outcome of endometrial cancer with p53 mutation. Indian J Surg Oncol 2022;13:580-6.
Watanabe T, Nanamiya H, Kojima M, Nomura S, Furukawa S, Soeda S, et al. Clinical relevance of oncogenic driver mutations identified in endometrial carcinoma. Transl Oncol 2021;14:101010.
Matsumoto N, Manrai P, Rottmann D, Wu X, Assem H, Hui P, et al. Correlative assessment of p53 immunostaining patterns and TP53 mutation status by next-generation sequencing in high-grade endometrial carcinomas. Int J Gynecol Pathol 2023;42:567-75.
Singh N, Piskorz AM, Bosse T, Jimenez-Linan M, Rous B, Brenton JD, et al. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies. J Pathol 2020;250: 336-45.
McCluggage WG, Soslow RA, Gilks CB. Patterns of p53 immunoreactivity in endometrial carcinomas: ‘all or nothing’ staining is of importance. Histopathology 2011;59:786-8.
Berchuck A, Boyd J. Molecular basis of endometrial cancer. Cancer 1995;76:2034-40.
Edmondson RJ, Crosbie EJ, Nickkho-Amiry M, Kaufmann A, Stelloo E, Nijman HW, et al. Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative. Gynecol Oncol 2017;146:327-33.
John PG, Hans EG, Michael CW, Zhen Z, Greg AM, William C. p53 expression as a prognostic indicator of 5-year survival in endometrial cancer. Gynecologic Oncology 1999;74:468-71.
León-Castillo A, de Boer SM, Powell ME, Mileshkin LR, Mackay HJ, Leary A, et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on prognosis and benefit from adjuvant therapy. J Clin Oncol 2020;38:3388-97.
Yang Y, Wu SF, Bao W. Molecular subtypes of endometrial cancer: Implications for adjuvant treatment strategies. Int J Gynaecol Obstet 2024;164:436-59.
Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program. Int J Gynecol Cancer 2022;33:109-17.
Bo M, Lien NH, John BM, Máire AD, Gregg SN, Cheng-Han L, et al. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. Gynecologic Oncology 2014;134:15-9.
Jumaah AS, Al-Haddad HS, McAllister KA, Yasseen AA. The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis. PLoS One 2022;17:e0263585.
Aline T, Lien NH, Melissa KM, Quentin N, Joyce L, Angela C, et al. Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment. Gynecologic Oncology 2016;143: 46-53.
Berek JS, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S, et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet 2023;162:383-94.
Dankai W, Pongsuvareeyakul T, Phinyo P, Tejamai C, Teerapakpinyo C, Cheewakriangkrai C, et al. Molecular-based classification of endometrial carcinoma in northern Thailand: impact on prognosis and potential for implementation in resource-limited settings. BMC Womens Health 2023;23:605.
Jamieson A, Vermij L, Kramer CJH, Jobsen JJ, Jürgemlienk-Schulz I, Lutgens L, et al. Clinical behavior and molecular landscape of stage I p53-abnormal low-grade endometrioid endometrial carcinomas. Clin Cancer Res 2023;29:4949-57.